Позаконазол – новый азольный антимикотик широкого спектра для профилактики и лечения инвазивных микозов


Климко Н.Н.

Инвазивные микозы являются частым осложнением у различных категорий иммунокомпрометированных пациентов, отличаясь тяжестью клинических проявлений и высокой атрибутивной летальностью. Многие возбудители инвазивных микозов характеризуются устойчивостью к применяемым в настоящее время противогрибковым препаратам, а некоторые из них – полирезистентны. Позаконазол – новый триазольный антимикотик второго поколения, который активен in vitro и in vivo в отношении большинства возбудителей инвазивных микозов, в т. ч. полирезистентных микромицетов. Клинические исследования показали высокую эффективность и безопасность применения этого препарата. В нашей стране разрешено применение позаконазола для профилактики инвазивных микозов у гематологических больных с длительной нейтропенией вследствие химиотерапии; получающих высокие дозы иммуносупрессоров реципиентов трансплантатов кроветворных стволовых клеток, а также для лечения инвазивных кандидоза, аспергиллеза, зигомикоза, криптококкоза, фузариоза, хромомикоза, мицетомы и кокцидиоидоза, рефрактерных к другим противогрибковым лекарственным средствам или при их непереносимости.

Литература





  1. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002;15:569–74.

  2. Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk Lymphoma 2004;45:669–80.

  3. Климко Н.Н., Веселов А.В. Новые препараты для лечения инвазивных микозов // Клиническая микробиология и антимикробная химиотерапия. 2003. № 5. С. 342–353.

  4. Ashley ED, Posaconazole AB. Drugs Today 2005;41(6):393–400.

  5. Groll A, Walsh T. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005;3(4):467–87.

  6. Boucher H, Groll A, Chiou C, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64(18):1997–2020.

  7. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004;48(1):137–42.

  8. Pfaller M, Messer S, Hollis R, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46(4):1032–37.

  9. Sabatelli F, Patel R, Mann P, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50(6):2009–15.

  10. Torres-Narbona M, Guinea J, Martinez-Alarcon J, et al. In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007;51(3):1126–29.

  11. Torres H, Hachem R, Chemaly R, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5(12):775–85.

  12. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47(9):2788–95.

  13. Conte JR, Golden JA, Krishna G, et al. Intra pulmonary pharmacokinetics-pharmacodynamics of posaconazole. 3 Advancer Against Aspergillosis 2008.

  14. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48(9):3543–51.

  15. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21(5):645–53.

  16. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51(2):495–502

  17. Naggapan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin infect Dis 2007;45:1610–17.

  18. Ullmann A, Cornely O, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50(2):658–66.

  19. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole Plasma Concentrations in Juvenile Patients With Invasive Fungal Infection. Antimicrob Agents Chemother 2007;51(3):812–18.

  20. Antachopoulos C, Walsh T. New agents for invasive mycoses in children. Curr Opin Pediatr 2005;17(1):78–87.

  21. Keating G. Posaconazole. Drugs 2005; 65(11): 1553–67.

  22. Pitisuttithum P, Negroni R, Graybill J, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56(4):745–55.

  23. Tobon A, Arango M, Fernandez D, et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. CID 20031;36(11):1488–91.

  24. Greenberg R, Mullane K, van Burik J, et al. Posaconazole as salvage therapy for Zygomycosis. Antimicrob Agents Chemother 2006; 50 (1):126–33.

  25. Van Burik J, Hare R, Solomon H, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. CID 2006;42(7):61–65.

  26. Rutar T, Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 2006;142(1):187–88.

  27. Page R, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007;27(2):290–98.

  28. Walsh T, Raad I, Patterson T, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. CID 2007;44(1):2–12.

  29. Raad I, Hachem R, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID 2006; 42(10):1398–403.

  30. Tu E, McCartney D, Beatty R, et al. Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592). Am J Ophthalmol 2007;143(2):222–27.

  31. Restrepo A,Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007;54(4):319–27.

  32. Ullmann A, Cornely O. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006;19(6):571–76.

  33. Barchiesi F, Spreghini E, Santinelli A, et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007;51(1):73–77.

  34. Cornely O, Maertens J, Winston D, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348–59.

  35. Ullmann A, Lipton J, Vesole D, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4): 335–47.

  36. Notheis G, Tarani L, Costantino F, et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006;1:37–41.

  37. De Decker K, Van Poucke S, Wojciechowski M, et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr Crit Care Med 2006;7(5):482–85.

  38. Sorensen J, Becker M, Porto L, et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses 2006;49:31–36.

  39. Chan Y, Goldwater P, Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J Paediatr Child Health 2007; 43(1–2):87–89.

  40. Raad I, Graybill J, Bustamante A, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. CID 2006;42(12):1726–34.

  41. Paugam A. The latest data on posaconazole. Med Mal Infect 2007;54(4):319–27.

  42. Walsh TJ, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disieases Society of America. Clin Infect Dis 2008;46: 327–60.

  43. NCCN Clinical Practice Guidelines in Oncology – v.1.2007. Prevention and Treatment of Cancer-Related Infections. www.nccn.org.

  44. Maertens JA, et al. Primary antifungal prophylaxis in leukemia patients. Eur J Cancer 2007; 5:43–49.

  45. НОКСАФИЛ® – Инструкция по медицинскому применению препарата 2007.



Бионика Медиа